Anavex Life Sciences Corp. (AVXL)Healthcare | Biotechnology | New York, United States | NasdaqGS
3.64 USD
+0.24
(7.059%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.71 +0.07 (1.923%) ⇧ (April 17, 2026, 7:44 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:10 a.m. EDT
AVXL is in a terminal decline phase triggered by the withdrawal of the EU bid for its Alzheimer's drug and subsequent lawsuits. Fundamentally, with a negative EPS, negative free cash flow, and a 50% drop in 4 weeks, the damage control is evident. The options market is pricing in a move down to $3.00 very quickly, and no one sees an immediate bounce. This is a 'do not touch' situation for new capital. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.254721 |
| AutoETS | 0.254721 |
| AutoARIMA | 0.254885 |
| MSTL | 0.257198 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.083 |
| Excess Kurtosis | -1.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 337,325,216 |
| Forward P/E | -26.00 |
| Beta | 1.18 |
| Website | https://www.anavex.com |
As of April 19, 2026, 1:10 a.m. EDT: Options flow reveals a highly bearish near-term structure. In the April 17 expiry (9 days out), Put OI at $3.00 (-17.6% strike) nearly doubles Call OI at $3.00, indicating a massive floor being built below the current price ($3.64). Intrinsic value puts at $3.00 show strong open interest with an 'ITM' flag, suggesting short sellers are positioning for a decline to that level. Conversely, the Call OI is heavily concentrated at $6.00 and $7.00 (far OTM), while ITM calls ($2.0) lack significant positioning. This 'long put, trade the mean' distribution suggests speculators are braced for a test of the lower support levels.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5844749 |
| Address1 | 630 5th Avenue |
| Address2 | 20th Floor |
| All Time High | 31.5 |
| All Time Low | 0.6 |
| Ask | 4.41 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 1,098,320 |
| Average Daily Volume3 Month | 1,502,182 |
| Average Volume | 1,502,182 |
| Average Volume10Days | 1,098,320 |
| Beta | 1.178 |
| Bid | 2.64 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.366 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.64 |
| Current Ratio | 20.874 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.68 |
| Day Low | 3.455 |
| Display Name | Anavex Life Sciences |
| Earnings Call Timestamp End | 1,770,643,800 |
| Earnings Call Timestamp Start | 1,770,643,800 |
| Earnings Timestamp | 1,770,643,800 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 205,576,192 |
| Eps Current Year | -0.325 |
| Eps Forward | -0.14 |
| Eps Trailing Twelve Months | -0.46 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.9102 |
| Fifty Day Average Change | -0.2702 |
| Fifty Day Average Change Percent | -0.069101326 |
| Fifty Two Week Change Percent | -58.44749 |
| Fifty Two Week High | 13.99 |
| Fifty Two Week High Change | -10.349999 |
| Fifty Two Week High Change Percent | -0.7398141 |
| Fifty Two Week Low | 2.61 |
| Fifty Two Week Low Change | 1.0300002 |
| Fifty Two Week Low Change Percent | 0.39463612 |
| Fifty Two Week Range | 2.61 - 13.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,154,525,400,000 |
| Float Shares | 89,783,179 |
| Forward Eps | -0.14 |
| Forward P E | -26.0 |
| Free Cashflow | -21,833,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.031170001 |
| Held Percent Institutions | 0.41571 |
| Implied Shares Outstanding | 92,671,758 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,444,176,000 |
| Last Split Factor | 1:4 |
| Long Business Summary | Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. |
| Long Name | Anavex Life Sciences Corp. |
| Market | us_market |
| Market Cap | 337,325,216 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_13580387 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -39,947,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 336,861,840 |
| Number Of Analyst Opinions | 2 |
| Open | 3.46 |
| Operating Cashflow | -34,075,000 |
| Operating Margins | 0.0 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 844 689 3939 |
| Post Market Change | 0.06999993 |
| Post Market Change Percent | 1.9230751 |
| Post Market Price | 3.71 |
| Post Market Time | 1,776,469,452 |
| Previous Close | 3.4 |
| Price Eps Current Year | -11.200001 |
| Price Hint | 4 |
| Price To Book | 2.6647146 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.812 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.24 |
| Regular Market Change Percent | 7.05882 |
| Regular Market Day High | 3.68 |
| Regular Market Day Low | 3.455 |
| Regular Market Day Range | 3.455 - 3.68 |
| Regular Market Open | 3.46 |
| Regular Market Previous Close | 3.4 |
| Regular Market Price | 3.64 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,520,845 |
| Return On Assets | -0.21558 |
| Return On Equity | -0.33635 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 92,671,758 |
| Shares Percent Shares Out | 0.2079 |
| Shares Short | 19,262,453 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 20,366,318 |
| Short Name | Anavex Life Sciences Corp. |
| Short Percent Of Float | 0.2164 |
| Short Ratio | 9.66 |
| Source Interval | 15 |
| State | NY |
| Symbol | AVXL |
| Target High Price | 24.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 22.0 |
| Target Median Price | 22.0 |
| Total Cash | 131,749,000 |
| Total Cash Per Share | 1.422 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.668525 |
| Two Hundred Day Average Change | -3.028525 |
| Two Hundred Day Average Change Percent | -0.45415217 |
| Type Disp | Equity |
| Volume | 1,520,845 |
| Website | https://www.anavex.com |
| Zip | 10,111 |